These press releases are for business and financial media.
-
- 19 December 2006
- EPO Announces European Nexium® Substance Patent Decision AstraZeneca today announced that the European Patent Office (EPO) has ruled that one of the European substance patents for Nexium® (EP 0652872) will be rejected, following an appeal from the German generic manufacturer Ratiopharm. The original patent expiry for this patent was 2014.
-
- 11 December 2006
- Egyptian Health Minister Opens AstraZeneca’s New $32M Manufacturing Plant near Cairo Egyptian Health Minister Dr. Hatem Mostafa El-Gabaly today opened a new $32 million tablet factory built by AstraZeneca near Cairo – the company’s first manufacturing investment in the Middle East. David Brennan, Chief Executive Officer of AstraZeneca, also attended the opening ceremony at the factory in 6th of October City.
-
- 05 December 2006
- AstraZeneca Commitment To China Recognised by Cathay Pacific Award In recent years AstraZeneca has become the leading multinational pharmaceutical company in China in prescription sales, has established 25 sales offices in major cities across the country, created a $134m state-of-the-art manufacturing facility in Wuxi, Jiang Su Province, and has committed a further $100m to Research and Development.
-
- 22 November 2006
- AstraZeneca signs distribution agreement with Par Pharmaceutical for an authorized generic version of TOPROL-XL AstraZeneca today announced it has entered into a supply and distribution agreement with Par Pharmaceutical to distribute an authorized generic version of metoprolol succinate in the United States. Currently, the authorized generic product will be distributed in the 25 mg dosage strength. The signing of this agreement does not affect the availability of AstraZeneca’s branded version of metoprolol succinate, TOPROL-XL. AstraZeneca will continue to manufacture and make TOPROL-XL available in the United
-
- 03 November 2006
- AstraZeneca Updates CytoFab™ Development Programme AstraZeneca today announced its intention to expand the development plan for CytoFab™, a treatment for severe sepsis, with the addition of a 480 - patient Phase II study programme.
-
- 26 October 2006
- Third Quarter and Nine Months Results 2006 Download the narrative and the figures
-
- 26 October 2006
- AstraZeneca Announces SAINT II Trial Results Showed No Efficacy in Acute Ischaemic Stroke Results from the SAINT II ( S troke A cute I schemic N XY-059 T reatment) trial, announced today by AstraZeneca, showed that the investigational drug NXY-059 did not meet its primary outcome of a statistically significant reduction in stroke-related disability, as assessed by the modified Rankin Scale (mRS) (p=0.33, odds ratio 0.94) compared to placebo.
-
- 20 October 2006
- FDA Approves AstraZeneca’s SEROQUEL® for Bipolar Depression Treatment AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL® (quetiapine fumarate) for the treatment of patients with depressive episodes associated with bipolar disorder. SEROQUEL already is approved for the treatment of acute manic episodes associated with bipolar I disorder and for the treatment of schizophrenia. SEROQUEL is now the first and only single medication approved by the FDA to treat both depressive and manic episodes associated with bipolar disorder.
-
- 19 October 2006
- AstraZeneca Submits EU and Canadian Regulatory Filings for Sustained Release Formulation SEROQUEL SR™ for the Treatment of Schizophrenia AstraZeneca today announced further submissions to Regulatory Authorities for the approval of the sustained release (SR) once-daily formulation of SEROQUEL® for the treatment of patients with schizophrenia, including Canada and a Marketing Authorisation Application (MAA) in the European Union (EU) under Mutual Recognition Procedure (MRP). The submission will cover all markets in the EU where SEROQUEL® is currently approved.
-
- 09 October 2006
- AstraZeneca Successfully Completes Mutual Recognition Procedure For Symbicort® Maintenance And Reliever Therapy (Symbicort SMART®) in the EU AstraZeneca today announced that it has successfully completed the European Union Mutual Recognition Procedure (MRP) for Symbicort ® Maintenance And Reliever Therapy (Symbicort SMART ® ). This new treatment approach enables patients to take control of their asthma and use just one inhaler for both maintenance and relief of asthma symptoms.
-
- 18 September 2006
- AstraZeneca Officially Opens Two Major Scientific Laboratories, As Latest Phase Of UK R&D Investment Programme AstraZeneca announces the official opening this week of two major scientific laboratories in the UK. These latest developments add to AstraZeneca’s significant investment in the UK, with the creation of over 550 new science-related jobs over the last seven years.
-
- 15 September 2006
- AstraZeneca and Schering AG Form Strategic Alliance to Develop Novel SERD Breast Cancer Drug AstraZeneca and Schering AG, Germany (FSE: SCH, NYSE: SHR) have formed a new alliance to co-develop and jointly commercialise Schering AG’s novel SERD (selective estrogen receptor downregulator) to treat breast cancer.
-
- 22 August 2006
- AstraZeneca UK Limited Completes Acquisition of Cambridge Antibody Technology Group plc Compulsory Acquisition Procedure Completed Subsequent Offer Period Closed AstraZeneca today announced that it has completed the compulsory acquisition procedure under the Interim Regulations and now owns 100 percent of the issued share capital of CAT.
-
- 02 August 2006
- AstraZeneca and Pozen Inc Sign Deal to Develop and Commercialise naproxen and esomeprazole Fixed Dose Combinations utilising Pozen’s Proprietary Technology for the Treatment of Chronic Pain AstraZeneca today announced an exclusive global agreement with Pozen Inc. (NASDAQ: POZN) to co-develop fixed dose combinations of naproxen and esomeprazole for chronic pain, utilising Pozen’s proprietary formulation technology. The fixed dose combinations have the potential to provide chronic pain sufferers with a new treatment with good efficacy and a low upper gastro-intestinal (GI) side-effect profile.
-
- 27 July 2006
- Second Quarter and Half Year Results 2006 "A strong second quarter, with sales up 10 percent and Earnings per Share up 41 percent; on track to achieve financial targets for the full year."
-
- 26 July 2006
- AstraZeneca PLC appoints new Non-Executive Director AstraZeneca today announced that John Varley is to join the Board of Directors as a Non-Executive Director with immediate effect. John Varley is the Group Chief Executive of Barclays Bank PLC. Louis Schweitzer, Chairman of AstraZeneca, said, “I am delighted that John Varley has agreed to join us. His extensive commercial and financial expertise will add considerable benefit to the work of the Board”.
-
- 22 July 2006
- AstraZeneca’s SYMBICORT® (budesonide/formoterol) Treatment For Asthma Approved By The FDA AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SYMBICORT® (budesonide/formoterol) for the maintenance treatment of asthma in patients age 12 and older.
-
- 18 July 2006
- AstraZeneca Submits an NDA For Sustained Release Formulation SEROQUEL SR(TM) For the Treatment of Schizophrenia AstraZeneca today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration for a sustained release (SR) once-daily formulation of SEROQUEL for the treatment of patients with schizophrenia. The clinical trials to support the US submission of SEROQUEL SR TM used a short titration period aimed at achieving a therapeutically effective dose by the second day of treatment. The Company also expects to make a SEROQUEL SR TM filing in the European Union towards the end of 2006.
-
- 12 July 2006
- Doctors tend to underestimate the emotional impact of COPD exacerbations - patients fear being hospitalised or dying Lund, Sweden 13 July 2006: New data from a multinational, interview-based patient study, published today in the medical journal CHEST, shed light on COPD patients’ comprehension, recognition, and experience of exacerbations and the burden associated with these events.
-
- 05 July 2006
- AstraZeneca And Abbott To Co-Develop And Co-Market A Single-Pill, Fixed-Dose Combination Of CRESTOR® And Next-Generation TriCor ® (ABT-335) In The United States AstraZeneca and Abbott announced today a collaboration to co-develop and market a combination treatment that will target three important blood lipids - LDL ("bad" cholesterol), HDL ("good" cholesterol), and triglycerides – in one single pill as part of a comprehensive treatment regimen for mixed lipid disorders.
-
- 30 June 2006
- Asthma patients chase symptoms rather than preventing the underlying disease June 30, 2006, Lund, Sweden - New data on the attitudes and behaviours of asthma patients just published in BMC Pulmonary Medicine highlight the need for a new strategy in asthma management.
-
- 28 June 2006
- Addition of budesonide to formoterol (Symbicort®) and/or a short-acting beta 2 agonist reduces the risk of mortality in patients with severe COPD compared to bronchodilators alone Important new data from the analysis of combined data from the two pivotal Symbicort® studies, announced today at the 5th International Multidisciplinary Conference on Chronic Obstructive Pulmonary Disease (COPD5) in Birmingham, reveals that budesonide added to formoterol (Symbicort®) and/or terbutaline, significantly reduces mortality in severe COPD over one year, compared to the bronchodilators formoterol and/or terbutaline alone.
-
- 22 June 2006
- Recommended Cash Offer by AstraZeneca UK Limited for Cambridge Antibody Technology Group plc Offer Declared Unconditional and Initial Offer Period Extended AstraZeneca announces that it has acquired, or received valid acceptances of the Offer in respect of, 37,261,730 CAT Shares in aggregate, representing approximately 86.7 per cent. of the CAT Shares to which the Offer relates
-
- 19 June 2006
- Biggest LDL-C Reduction Ever Shown In Patients Is Achieved With A CRESTOR Combination Therapy A combination treatment regimen of CRESTOR TM (rosuvastatin) 40 mg and ezetimibe 10 mg achieved an unprecedented 70 per cent reduction in LDL-C which is the largest reduction in LDL-C ever seen in a statin clinical trial. In just six weeks, this combination treatment also helped more high-risk patients (94 per cent) – whose LDL-C needs to be reduced to less than 100mg/dL– achieve their guideline LDL-C goals than those treated with CRESTOR alone (79 per cent ) (p0.001). These results from the EXPLORER
-
- 08 June 2006
- AstraZeneca Outlines Strategy to Further Strengthen Its Product Pipeline While Delivering Continued Sales and Earnings Growth AstraZeneca will provide an update on its strategy and development pipeline through to the end of the decade at a business review meeting to be held in London today.
-
- 26 May 2006
- AstraZeneca Announces $100 Million R&D Investment in China AstraZeneca today announced its intention to invest $100 million in R&D in China over the next three years, focusing on the benefit and value of innovative medicines for Chinese patients.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 20-Nov-2009 22:46 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
